The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal ...
The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal ...
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Histidine modifications of proteins are broadly based on chemical methods triggering N ...
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada Department ...
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Ribosomal action is facilitated by the ...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback